The authors reply: Empagliflozin and progression of kidney disease in Type 2 diabetes

New England Journal of Medicine

Volumn 375, Issue 18, 2016, Pages 1801-1802

  Wanner, Christoph ^a   Inzucchi, Silvio E ^b   Zinman, Bernard ^c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EMPAGLIFLOZIN; PLACEBO;

BLOOD PRESSURE REGULATION; DRUG EFFICACY; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RENOVASCULAR HYPERTENSION; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84994180780     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1611290     Document Type: Letter

References (5)

1. Vallon V, Gerasimova M, Rose MA, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 2014; 306: F194-204
2. Skrtić M, Yang GK, Perkins BA, et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia 2014; 57: 2599-602
3. Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129: 587-97
4. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 2016; 134: 752-72
5. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93.